Impact Biomedical (IBO) Receivables - Net (2024 - 2025)
Impact Biomedical (IBO) posted Receivables - Net of $5000.0 for Q4 2025, down 97.49% on a QoQ basis from $199000.0 in Q3 2025, and down 97.51% year-over-year from $201000.0 in Q4 2024.
Impact Biomedical (IBO) Receivables - Net (2024 - 2025) Analysis & Trends
Impact Biomedical's Receivables - Net history runs 2 years deep, the most recent figure standing at $5000.0 for Q4 2025.
- Quarterly Receivables - Net fell 97.51% year-over-year to $5000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5000.0 (down 97.51% YoY) and the FY2025 annual result came in at $5000.0, down 97.51% from the prior year.
- Receivables - Net was $5000.0 for Q4 2025 at Impact Biomedical, down from $199000.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $201000.0 in Q4 2024 and bottomed at $5000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Impact Biomedical | 47.44 Mn | 50.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Sep 30, 2025 | 199,000.00 |
| Sep 30, 2025 | 199,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Jun 30, 2024 | 128,000.00 |
| Jun 30, 2024 | 128,000.00 |
| Mar 31, 2024 | 128,000.00 |
| Mar 31, 2024 | 128,000.00 |